Afraxis Raises $1.2M in Venture Funding

Xconomy San Diego — 

San Diego-based aFraxis, which has completed pre-clinical testing of a promising compound for treating fragile X syndrome, the most common cause of inherited mental impairment, has raised $1.2 million in a venture round targeting $6 million, according to a recent regulatory finding. San Diego’s Avalon Ventures already has invested about $6 million since the company was founded three years ago.